NASDAQ:DXCM - Dexcom Stock Price, Price Target & More

Dexcom trades on the NASDAQ under the ticker symbol "DXCM."

Dexcom (NASDAQ:DXCM) issued its quarterly earnings results on Wednesday, May, 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.32). The medical device company had revenue of $184.40 million for the quarter, compared to analyst estimates of $172.66 million. Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The company's quarterly revenue was up 29.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.49) earnings per share. View Dexcom's Earnings History.

Dexcom is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Dexcom.

19 Wall Street analysts have issued 1-year target prices for Dexcom's shares. Their predictions range from $40.00 to $100.00. On average, they anticipate Dexcom's share price to reach $69.7941 in the next twelve months. View Analyst Ratings for Dexcom.

Dexcom saw a decrease in short interest in May. As of May 15th, there was short interest totalling 9,759,794 shares, a decrease of 21.3% from the April 30th total of 12,398,444 shares. Based on an average trading volume of 1,605,191 shares, the short-interest ratio is currently 6.1 days. Currently, 11.4% of the shares of the stock are sold short.

Some companies that are related to Dexcom include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD), Globus Medical (GMED), Haemonetics (HAE), NovoCure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).

Media stories about DXCM stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dexcom earned a coverage optimism score of 0.06 on Accern's scale. They also gave press coverage about the medical device company an impact score of 44.36 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Dexcom's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.15%), BlackRock Inc. (4.41%), JPMorgan Chase & Co. (2.94%), OppenheimerFunds Inc. (1.70%), Franklin Resources Inc. (1.33%) and Point72 Asset Management L.P. (1.11%). Company insiders that own Dexcom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for Dexcom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Russell Investments Group Ltd., Massachusetts Financial Services Co. MA, Baillie Gifford & Co., Compagnie Lombard Odier SCmA, Thornburg Investment Management Inc., Allianz Asset Management GmbH and Allianz Asset Management GmbH. Company insiders that have sold Dexcom company stock in the last year include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for Dexcom.

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Point72 Asset Management L.P., Neuberger Berman Group LLC, Federated Investors Inc. PA, JPMorgan Chase & Co., Columbus Circle Investors, Frontier Capital Management Co. LLC and Chicago Capital LLC. View Insider Buying and Selling for Dexcom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $88.00.

Dexcom has a market capitalization of $7.71 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Dexcom employs 2,990 workers across the globe.

Dexcom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]